Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:DBVT NASDAQ:PMVP NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$6.89-4.2%$8.61$56.35▼$105.00$199.71M0.9512,438 shs143,073 shsDBVTDBV Technologies$9.00+5.8%$9.50$2.20▼$12.78$233.09M-0.5826,058 shs24,525 shsPMVPPMV Pharmaceuticals$1.40-1.4%$1.16$0.81▼$1.82$73.77M1.51313,187 shs154,729 shsVORVor Biopharma$2.10+1.4%$1.22$0.13▼$3.29$262.42M2.048.21 million shs2.45 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+4.51%-13.69%-28.03%-42.39%-88.71%DBVTDBV Technologies+5.76%-5.95%-12.62%+0.56%+85.57%PMVPPMV Pharmaceuticals-1.41%-0.71%+27.27%+40.48%-15.66%VORVor Biopharma+1.45%-4.55%+44.83%+217.51%+126.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADBVTDBV Technologies3.6233 of 5 stars4.45.00.00.00.92.50.6PMVPPMV Pharmaceuticals3.5341 of 5 stars3.55.00.00.03.22.50.6VORVor Biopharma3.269 of 5 stars4.30.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ADBVTDBV Technologies 2.80Moderate Buy$14.7563.89% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50292.86% UpsideVORVor Biopharma 2.60Moderate Buy$5.63168.03% UpsideCurrent Analyst Ratings BreakdownLatest PMVP, VOR, AVTE, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform5/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ADBVTDBV Technologies$4.15M59.40N/AN/A$3.15 per share2.86PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%N/APMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)VORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest PMVP, VOR, AVTE, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/A7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 million5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78DBVTDBV TechnologiesN/A2.450.72PMVPPMV PharmaceuticalsN/A16.7516.75VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ADBVTDBV Technologies71.74%PMVPPMV Pharmaceuticals90.20%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%DBVTDBV Technologies1.44%PMVPPMV Pharmaceuticals7.57%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableDBVTDBV Technologies8027.39 million27.00 millionOptionablePMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionableVORVor Biopharma140124.96 million65.45 millionNot OptionablePMVP, VOR, AVTE, and DBVT HeadlinesRecent News About These CompaniesAnalysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63August 2 at 2:21 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?July 30 at 2:57 AM | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 30 at 2:45 AM | marketbeat.comVor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to BoardJuly 29, 2025 | insidermonkey.comVor Biopharma Announces Key Leadership ChangesJuly 25, 2025 | theglobeandmail.comVor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% dropJuly 23, 2025 | finance.yahoo.comVor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of DirectorsJuly 21, 2025 | globenewswire.comH.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price TargetJuly 20, 2025 | msn.comVor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing ZurawJuly 18, 2025 | quiverquant.comQVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | globenewswire.comVor Bio Appoints Qing Zuraw, M.D. as Chief Development OfficerJuly 17, 2025 | globenewswire.comVor Biopharma Names Sandy Mahatme Chief Financial OfficerJuly 11, 2025 | marketwatch.comVor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 11, 2025 | finanznachrichten.deVor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerJuly 10, 2025 | globenewswire.comVor Biopharma: Not So Sure About This Surge, And Do Mind The WarrantsJuly 8, 2025 | seekingalpha.comBiopharma layoffs for first half of the year jump 32% YOYJuly 8, 2025 | fiercebiotech.comFVor Biopharma Target of Unusually High Options Trading (NYSE:VOR)July 8, 2025 | marketbeat.comBoston’s biotech sector reels due to Trump health policy uncertaintyJuly 6, 2025 | ft.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5, 2025 | marketbeat.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2, 2025 | marketbeat.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendThis ASML Dip Could Be Gone Before You Know It—Don’t Miss OutBy Thomas Hughes | July 16, 2025View This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out3 Reasons Palo Alto Networks Is Becoming a Wall Street FavoriteBy Nathan Reiff | July 22, 2025View 3 Reasons Palo Alto Networks Is Becoming a Wall Street FavoriteSizzling Insider Buys for Your High-Yield WatchlistBy Thomas Hughes | July 8, 2025View Sizzling Insider Buys for Your High-Yield WatchlistTop 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]By MarketBeat Staff | July 29, 2025View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]PMVP, VOR, AVTE, and DBVT Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$6.89 -0.30 (-4.17%) As of 08/1/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.DBV Technologies NASDAQ:DBVT$9.00 +0.49 (+5.76%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$9.03 +0.03 (+0.33%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.PMV Pharmaceuticals NASDAQ:PMVP$1.40 -0.02 (-1.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Vor Biopharma NYSE:VOR$2.10 +0.03 (+1.45%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 -0.06 (-2.86%) As of 08/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
